Literature DB >> 21530185

To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?

Gigi H H van de Loo-Neus1, Nanda Rommelse, Jan K Buitelaar.   

Abstract

ADHD is a common neuropsychiatric disorder with a strong persistence over time. Medication is frequently used in the clinical management of ADHD. After response, medication is typically prescribed for months to years. It is unclear whether extended medication treatment provides long-term benefits and how long it should be continued. Furthermore, there is concern about the long-term safety of ADHD medication. The aim of this systematic review is to address these issues and provide recommendations about the decision to stop or not to stop ADHD medication. We performed a search in PubMed and focused on medication studies with a treatment longer than 12weeks in subjects 6-18years old. Extended placebo-controlled double-blind parallel studies are not available. Placebo-controlled discontinuation studies and prospective long-term observational treatment studies provide evidence that medication management leads to a substantial reduction of ADHD symptoms and less impairment of functioning for a period of about 2years. There is limited and inconsistent evidence for long-term advantage of medication treatment beyond symptom control, such as improved social functioning, academic achievement, employment status and less adverse psychiatric outcome. In terms of safety, long-term effects of medication on growth, blood pressure and heart rate are limited and the occurrence of suicidal, psychotic and manic symptoms is rare. Animal data about neurotoxic effects of psycho stimulants cannot be directly extrapolated to humans. Therefore, clinical decisions about starting, continuing, and stopping of ADHD medication should be made on an individual basis. Medication free periods should be implemented at regular times to investigate the need for an ongoing benefit of medication. Unfounded assumptions about continuing benefit of medication use should be abandoned. Careful monitoring of side effects is necessary and must be able to detect early alarming signals.
Copyright © 2011 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530185     DOI: 10.1016/j.euroneuro.2011.03.008

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  31 in total

1.  Is there a future for restricted elimination diets in ADHD clinical practice?

Authors:  Nanda Rommelse; Jan Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-04       Impact factor: 4.785

2.  Attention-deficit/hyperactivity disorder: seeking the right balance between over- and undertreatment.

Authors:  Pieter J Hoekstra; Andrea Dietrich
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-08       Impact factor: 4.785

3.  Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Authors:  Anouk Schrantee; Hyke G H Tamminga; Cheima Bouziane; Marco A Bottelier; Esther E Bron; Henk-Jan M M Mutsaerts; Aeilko H Zwinderman; Inge R Groote; Serge A R B Rombouts; Ramon J L Lindauer; Stefan Klein; Wiro J Niessen; Brent C Opmeer; Frits Boer; Paul J Lucassen; Susan L Andersen; Hilde M Geurts; Liesbeth Reneman
Journal:  JAMA Psychiatry       Date:  2016-09-01       Impact factor: 21.596

4.  A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants.

Authors:  James G Waxmonsky; William E Pelham; Adriana Campa; Daniel A Waschbusch; Tan Li; Rebecca Marshall; Lysett Babocsai; Hugh Humphery; Elizabeth Gnagy; James Swanson; Tomasz Hanć; Negar Fallahazad; William E Pelham
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-08-29       Impact factor: 8.829

5.  Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.

Authors:  Leanna Kalinowski; Carly Connor; Rathini Somanesan; Emily Carias; Kaleigh Richer; Lauren Smith; Connor Martin; Macauley Mackintosh; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  Dev Psychobiol       Date:  2019-08-27       Impact factor: 3.038

6.  A Randomized Controlled Trial of an Integrated Brain, Body, and Social Intervention for Children With ADHD.

Authors:  Stephanie D Smith; Lawrence A Vitulano; Liliya Katsovich; Shuaixing Li; Christina Moore; Fenghua Li; Heidi Grantz; Xixi Zheng; Virginia Eicher; Selin Aktan Guloksuz; Yi Zheng; Jinxia Dong; Denis G Sukhodolsky; James F Leckman
Journal:  J Atten Disord       Date:  2016-05-13       Impact factor: 3.256

7.  A 6-month follow-up of an RCT on behavioral and neurocognitive effects of neurofeedback in children with ADHD.

Authors:  Katleen Geladé; Tieme W P Janssen; Marleen Bink; Jos W R Twisk; Rosa van Mourik; Athanasios Maras; Jaap Oosterlaan
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-11-02       Impact factor: 4.785

Review 8.  Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder?

Authors:  Joshua M Langberg; Stephen P Becker
Journal:  Clin Child Fam Psychol Rev       Date:  2012-09

9.  Is Physical Activity Causally Associated With Symptoms of Attention-Deficit/Hyperactivity Disorder?

Authors:  Anna-Sophie Rommel; Paul Lichtenstein; Mina Rydell; Ralf Kuja-Halkola; Philip Asherson; Jonna Kuntsi; Henrik Larsson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-05-05       Impact factor: 8.829

10.  Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians.

Authors:  Chris J Bushe; Nicola Savill
Journal:  J Cent Nerv Syst Dis       Date:  2011-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.